查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1866178

脆性X综合症：策略市场分析及研发管线展望（2025）

Fragile X syndrome: Strategic Market Insights & Pipeline Outlook - 2025
出版日期: | 出版商: Mellalta Meets LLP | 英文 100 Pages | 商品交期: 7-10个工作天内

价格
简介目录

脆性X症候群 (FXS) 仍然是研究最深入的罕见神经发育障碍之一，但目前仍缺乏有效的治疗方案。对突触功能障碍的深入理解以及新分子标靶的出现，例如 mGluR5、GABA 和 FMRP 的重新激活，有望催生新一代疾病修饰疗法。儘管经过数十年的研究，目前尚无任何疾病修饰疗法获得批准，这代表着一个价值数十亿美元的未开发市场，对于那些寻求突破对症治疗的创新公司而言，这是一个巨大的机会。

FXS 是导致智障和自闭症最常见的遗传原因，代表着巨大的未满足医疗需求。其单基因特性（FMR1 基因沉默）提供了一个清晰、可操作的生物学靶点，并已被广泛验证。儘管药物研发管线历来充满失败，但这些挫折至关重要，提供了宝贵的经验教训，如今这些经验教训构成了更完善的临床策略的基础。

作用机转的演进

脆性X症候群（FXS）治疗的作用机转理论已发生显着变化。早期疗法，如mGluR5拮抗剂（如诺华的Mavogrant和罗氏的Basimgrant），在后期临床试验中失败，主要原因是患者异质性和生物标记不完善。然而，这些研究验证了生物学通路，并建立了一个测试平台，目前的药物研发人员可以更精准地利用该平台。

磷酸二酯酶9A（PDE9A）已成为药物研发的高价值靶点，特别是因为其在心血管疾病和神经退化性疾病中发挥重要作用。脆性X症候群透过调节环核苷酸水平，提供了一种新的作用机制，这可能为心臟衰竭（HFpEF、HFrEF）、阿兹海默症和精神分裂症的治疗带来突破性进展。然而，儘管前景可期，目前尚无任何脆性X症候群的治疗方法获准用于临床，这为药物研发者和投资者带来了高风险、高回报的机会。

市场概况：竞争格局与扩张态势

脆性X症候群治疗市场充满活力，许多大型公司正在开发多种候选药物。主要趋势包括：

1. Tetra/Shionogi - BPN14770（zatachromast）正在推进IIb期临床试验，在认知和语言功能方面显示出令人鼓舞的结果。

2. Zynerba Pharmaceuticals - 大麻素透皮疗法（Zygel）在III期临床试验中结果喜忧参半，但为监管制定提供了有益的先例。

临床开发正在加速，具体表现如下：

1. 50%的脆性X症候群治疗药物正处于III期临床试验阶段。

2. II期临床试验成功率：41%

3. I期临床试验成功率：9%

商业机会：市场成长与投资潜力

预计2030年，脆性X症候群市场规模将达7亿美元。这一快速成长主要受以下因素驱动：

1. 新生儿筛检与基因检测的普及

2. 对罕见神经发育障碍的投资增加

3. 适应症范围扩大的潜力（例如，雷特氏症候群、自闭症谱系障碍、智障）

4.美国、欧盟和日本对罕见疾病的政策和报销支持。

目前，脆性X症候群尚无核准疗法，因此早期投资可带来先发优势，尤其是在合作、收购和授权协议方面。

Mellalta Meets "脆性X症候群策略市场洞察与研发管线展望 - 2025" 报告的策略洞察

Mellalta Meets "脆性X症候群策略市场分析与研发管线展望 - 2025" 报告提供深入的市场情报，涵盖：

1. 研发管线分析 - 依公司及研发阶段划分的产品状态

2. 临床试验分析 - 主要地区、疗法和试验结果

3.竞争情报－收购目标、授权协议与融资趋势

4.适应症优先排序 - 辨识药物研发中的高价值机会

目录

第一章：报告概述

第二章：概述

  • 脆性X症候群
  • 脆性X症候群的潜在问题
  • 脆性X症候群的病理生理学
  • 未满足的需求

第三章 脆性X症候群研发管线分析

  • 概述
  • 依适应症/阶段划分的在研产品
  • 依研发阶段划分的在研产品
  • 脆性X症候群的竞争格局
  • 依公司和研发阶段划分的在研产品
  • 脆性X症候群的临床和监管资讯时间线

第四章：脆性X症候群的收购、授权与合作协议

  • 脆性X症候群的收购、授权和交易价值
  • 脆性X症候群的收购和授权（依交易类型和阶段划分的总价值）
  • 在研的有前景的技术

第五章：脆性X症候群的研发管线概览

  • 概述
  • 后期资产比较表
  • 脆性X症候群研发管线药物概况
  • Zatolumilast（Tetra Discovery Partners）
  • ZYN002（Zynerba Pharmaceuticals, Inc.）
  • MRM-3379（Mirum Pharmaceuticals, Inc.）公司）
  • SPG601（Spinogenix）
  • OV101（Healx AI）
  • 其他

第六章：脆性X症候群的未来展望

第七章：SWOT分析

第八章：附录

简介目录

Fragile X syndrome (FXS) represents one of the most advanced yet underserved areas in rare neurodevelopmental disorders. With increasing understanding of synaptic dysfunction and emerging molecular targets such as mGluR5, GABA, and FMRP reactivation, the field is poised for a new generation of disease-modifying therapeutics. Despite decades of research, there are no approved disease-modifying drugs, underscoring a multi-billion-dollar untapped opportunity for companies innovating beyond symptomatic management.

As the most common inherited cause of intellectual disability and autism, FXS presents a significant unmet need. Its monogenic origin-the silencing of the FMR1 gene-provides a clear, actionable biological target that has been extensively validated. While the therapeutic pipeline has been marked by historical failures, these setbacks have been critical, providing invaluable lessons that are now informing more sophisticated clinical strategies.

Evolution of Mechanism of Action

The mechanistic rationale for FXS therapeutics has evolved dramatically. Early approaches, such as mGluR5 antagonists (Novartis's mavoglurant and Roche's basimglurant), failed in late-stage trials-largely due to patient heterogeneity and underdeveloped biomarkers. However, these studies validated the biological pathway and established trial infrastructure that current players now leverage with greater precision.

Phosphodiesterase 9A (PDE9A) has emerged as a high-value target in drug development, particularly for its role in cardiovascular and neurodegenerative diseases. By modulating cyclic nucleotide levels, Fragile X Syndromes offer a novel mechanism of action that could translate into groundbreaking therapies for heart failure (HFpEF, HFrEF), Alzheimer's disease, and schizophrenia. However, despite their promise, no Fragile X Syndrome has been approved for clinical use yet-leaving a high-risk, high-reward opportunity for drug developers and investors.

Market Overview: Competitive and Expanding Landscape

The Fragile X Syndromes market is highly dynamic, with many active drug candidates in development by key players, including:

1) Tetra/Shionogi - advancing BPN14770 (zatakromast) in Phase IIb with promising cognition and language outcomes.

2) Zynerba Pharmaceuticals - cannabinoid-based transdermal therapy (Zygel) showing mixed results in Phase III but providing useful regulatory precedent.

Clinical progress is accelerating, with:

1) 50% of Fragile X Syndromes in Phase III trials

2) 41% in Phase II trials

3) 9% in Phase I trials

Commercial Opportunity: Market Growth & Investment Potential

The broader Fragile X Syndrome market is projected to reach $700 million by 2030. This surge is fueled by:

1) Increasing newborn screening and genetic testing adoption.

2) Rising investment in rare neurodevelopmental disorders.

3) Expanding cross-indication potential (e.g., Rett, ASD, intellectual disability).

4) Policy and reimbursement support for orphan conditions in the U.S., EU, and Japan.

With no approved Fragile X Syndromes yet, early-stage investments could lead to first-mover advantages, especially in partnerships, acquisitions, and licensing deals.

Strategic Insights from Mellalta Meets' 2025 Report

The Fragile X Syndrome - Strategic Market Insights & Pipeline Outlook 2025 Report by Mellalta Meets provides in-depth market intelligence, covering:

1) Pipeline Breakdown - Companies, Products in various development phases.

2) Clinical Trial Analysis - Key regions, interventions, and trial outcomes.

3) Competitive Intelligence - Acquisition targets, licensing deals, and funding trends.

4) Indication Prioritization - Identifying high-value opportunities in drug development.

Table of Content

1. REPORT OVERVIEW

2. OVERVIEW

  • 2.1. Fragile X Syndromes
  • 2.2. Potential Concern with Fragile X Syndromes
  • 2.3. Fragile X Syndromes: Pathophysiology
  • 2.4. Unmet Needs

3. FRAGILE X SYNDROME PIPELINE ANALYSIS

  • 3.1. Overview
  • 3.2. Assets by Indication/Phase
  • 3.3. Pipeline Products by Stage of Development
  • 3.4. Fragile X Syndrome Competitive Landscape
  • 3.5. Pipeline Products by Company and Phases
  • 3.6. Fragile X Syndrome Clinical & Regulatory Timelines

4. FRAGILE X SYNDROME ACQUISITIONS, LICENSING AND COLLABORATION DEALS

  • 4.1. Fragile X Syndrome Acquisitions, Licensing and Deal values
  • 4.2. Fragile X Syndrome Acquisitions, Licensing by Transaction type and total amount size by Phases
  • 4.3. Promising Technologies Under development

5. Fragile X Syndrome PIPELINE LANDSCAPE

  • 5.1. Profile at Glance
  • 5.2. Late-Stage Assets Comparisons At-a-glance
  • 5.3. Fragile X Syndrome Pipeline Drug Profiles
    • 5.3.1. Zatolmilast (Tetra Discovery Partners)
      • 5.3.1.1. Product Profile & Description
      • 5.3.1.2. Collaborations
      • 5.3.1.3. Other Developments
      • 5.3.1.4. Clinical Trials
    • 5.3.2. ZYN002 (Zynerba Pharmaceuticals, Inc.)
      • 5.3.2.1. Product Profile & Description
      • 5.3.2.2. Collaborations
      • 5.3.2.3. Other Developments
      • 5.3.2.4. Clinical Trials
    • 5.3.3. MRM-3379 (Mirum Pharmaceuticals, Inc.)
      • 5.3.3.1. Product Profile & Description
      • 5.3.3.2. Collaborations
      • 5.3.3.3. Other Developments
      • 5.3.3.4. Clinical Trials
    • 5.3.4. SPG601 (Spinogenix)
      • 5.3.4.1. Product Profile & Description
      • 5.3.4.2. Collaborations
      • 5.3.4.3. Other Developments
      • 5.3.4.4. Clinical Trials
    • 5.3.5. OV101 (Healx AI)
      • 5.3.5.1. Product Profile & Description
      • 5.3.5.2. Collaborations
      • 5.3.5.3. Other Developments
    • 5.3.6. Others...

6. FRAGILE X SYNDROME FUTURE PROSPECTS

7. SWOT ANALYSIS

8. APPENDIX